Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parenteral iron therapy options.

Scott B Silverstein1, George M Rodgers

  • 1Department of Pharmacy Services, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA.

American Journal of Hematology
|April 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for Studying the Role of ADAMTS13 in Angiogenesis.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Pregnancy outcomes in women with Von Willebrand disease: a statewide cohort study.

Research and practice in thrombosis and haemostasis·2026
Same author

Hereditary Antithrombin Deficiency in Pediatric Patients: Pathophysiology, Clinical Features, Diagnosis, and Antithrombin Replacement Therapy.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders.

Journal of blood medicine·2025
Same author

Response to: the role of oral ferric pyrophosphate protected by a phospholipid bilayer plus a sucrester matrix for treating cancer-related anemia.

Expert review of hematology·2025
Same author

Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same journal

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026
Same journal

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same journal

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

American journal of hematology·2026
See all related articles

Parenteral iron therapy offers alternatives for patients unresponsive to oral iron. Available iron dextran, ferric gluconate, and iron sucrose products provide options to manage iron deficiency anemia and potentially reduce red blood cell transfusions.

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Oral iron therapy is not always effective for iron deficiency anemia.
  • Parenteral iron is indicated for specific patient groups, including those unresponsive to oral iron or undergoing recombinant erythropoietin therapy.

Purpose of the Study:

  • To review the available parenteral iron products.
  • To compare the advantages and disadvantages of iron dextran, ferric gluconate, and iron sucrose.
  • To discuss key factors including safety, dosing, and cost.

Main Methods:

  • Literature review of available parenteral iron preparations.
  • Comparative analysis of product characteristics.

Main Results:

  • Three parenteral iron products are available: iron dextran, ferric gluconate, and iron sucrose.

Related Experiment Videos

  • Each product has distinct profiles regarding risks (e.g., anaphylaxis), dosage, and cost.
  • Parenteral iron preparations offer alternatives to red blood cell transfusions.

    • Conclusions:

    • The availability of multiple parenteral iron formulations enhances treatment options for iron deficiency anemia.
    • Careful consideration of product-specific factors is necessary for optimal patient management.
    • Parenteral iron may reduce the reliance on blood transfusions for anemic patients.